United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - azathioprine - oral tablet - 50mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - azathioprine - oral tablet - 50mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

healthcare pharma ltd - azathioprine - oral tablet - 50mg

Jordan - Inggeris - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - azathioprine 50 mg - 50 mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - azathioprine - oral tablet - 25mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - azathioprine - oral tablet - 50mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: croscarmellose sodium; magnesium stearate; indigo carmine; purified water; titanium dioxide; gelatin; iron oxide red; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; povidone; microcrystalline cellulose; purified water; sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; magnesium stearate; iron oxide yellow; butan-1-ol; shellac; industrial methylated spirit; iron oxide black; lecithin; xanthan gum; glyceryl monostearate; benzoic acid; methylcellulose; simethicone; glyceryl distearate; peg-10 stearate; sorbic acid; dimeticone 5000 - imulate is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. imulate is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 meters square receiving allogeneic renal transplants (refer dosage and administration section).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; ethanol; glycerol; titanium dioxide; peg-40 hydrogenated castor oil; gelatin; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").